Sector News

J&J, Pfizer, Novartis are the in-demand pharmas among job-seekers, LinkedIn says

November 6, 2014
Life sciences
Hiring and keeping good employees is as much of a challenge in the drug business as it is anywhere else. So, it’s always nice to know that would-be job seekers think your company is swell.
 
Here’s the latest gauge of drugmakers’ status in the world of recruiting: LinkedIn ranked the 100 most “InDemand Employers” in the world, using a combination of various stats drawn from its membership ranks and its members’ online activities. Pharma didn’t exactly dominate the list–far more tech companies populate it, for instance. But a few drugmakers stood out.
 
Pfizer, for instance. The pharma behemoth came in at 17th on the list, with 71,000 employees on LinkedIn and a heavy bent toward the sales side. The company’s “top skills”–as determined by LinkedIn endorsements, surveys and the like–were pharma sales and sales effectiveness. Close behind, in 21st place, was Novartis, whose ranks also won kudos for sales effectiveness, but picked up an additional backing in oncology. The Swiss drugmaker has 50,000 workers on the site, LinkedIn says.
 
Bayer won 28th place, with 15,000 employees on LinkedIn and similar sales endorsements to Pfizer’s. Somewhat farther down the list was Roche, in 51st place, with 39,000 workers on the site and endorsement that leaned toward oncology and biotech, rather than sales. GlaxoSmithKline continued the sales-oriented trend in 75th place; some 68,000 of its employees are active on LinkedIn.
 
But the highest-ranked drugmaker was Johnson & Johnson, whose LinkedIn image extends past pharma and into devices and FDA expertise. About 52,000 J&J employees are on LinkedIn, and according to FiercePharmaMarketing research, the company maintains several different pages on the social networking site.
 
Which brings us to a caveat: The LinkedIn image ranking isn’t just about a company’s attractiveness to potential applications. It says as much about social-media strategy and employee networking–specifically on LinkedIn. So, if you’re disappointed to see your company left off this list, try stepping up the action on the site. If not, don’t despair. Your recruiting efforts may be paying off somewhere else.
 
– check out the LinkedIn list
 
By Tacy Staton
 

Related News

September 22, 2020

GSK’s Zejula and AZ’s Lynparza leap toward broader EU approval

Life sciences

GlaxoSmithKline’s Zejula and AstraZeneca’s Lynparza have both moved towards EU approval in new indications after receiving positive opinions from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human […]

September 22, 2020

Roche acquires Irish biotech firm Inflazome

Life sciences

Swiss pharma company Roche is set to acquire Irish biotech firm Inflazome for an upfront payment of $449m (€380m). In addition to the upfront payment, Inflazome is also eligible to […]

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]